Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations

In patients with rheumatic diseases undergoing immunosuppressive treatment, hepatitis B virus reactivation (HBVr) has been long recognized as a major treatment-related adverse event with substantial morbidity and mortality. Because HBVr is easily preventable with appropriate screening and monitoring...

Descripción completa

Detalles Bibliográficos
Autores principales: Koutsianas, Christos, Thomas, Konstantinos, Vassilopoulos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
When Rheumatology and Infectious Disease Come Together
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076579/
https://www.ncbi.nlm.nih.gov/pubmed/32206094
http://dx.doi.org/10.1177/1759720X20912646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076579/
https://www.ncbi.nlm.nih.gov/pubmed/32206094
http://dx.doi.org/10.1177/1759720X20912646

Ejemplares similares